Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo-Controlled Study of Silodosin to Facilitate Urinary Stone Passage

NCT01144949 is registered in ClinicalTrials.gov with Watson Pharmaceuticals as lead sponsor.

NCT NCT01144949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01144949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo-Controlled Study of Silodosin to Facilitate Urinary Stone Passage
Lead sponsor
Watson Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2010
Completion date
July 31, 2012
Enrollment
239 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

kidney stones, ureteral calculi, urolithiasis